

## From the INTERNATIONAL SEARCHING AUTHORITY

То:					PCT				
	see form	PCT/ISA/220 E R	I N G A N G E C E I V E D 19. jan. 2005 Gewerblicher Rechtsschutz	INTERNATION (F	TEN OPINION OF THE NAL SEARCHING AUTHORITY PCT Rule 43 <i>bis</i> .1)				
	licant's or agent's file form PCT/ISA/2			FOR FURTHER A See paragraph 2 below					
PC.	national application T/EP2004/05226	35	International filing date (d 22.09.2004	24.09.2003					
International Patent Classification (IPC) or both national classification and IPC A61M15/00 Applicant ALTANA PHARMA AG									
This opinion contains indications relating to the following items:									
	Box No. I Basis of the opinion								
☐ Box No. II Priority									
	☐ Box No. III			ard to novelty, inventive	e step and industrial applicability				
	☐ Box No. IV ☐ Box No. V	Lack of unity of invention  Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement							
	☐ Box No. VI	Certain docum		,, ,					
	☑ Box No. VII	Certain defect	s in the international app	lication					
	☐ Box No. VIII	Certain observ	ations on the internation	al application					
2.	FURTHER ACTI	ION							
	If a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA"). However, this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notifed the International Bureau under Rule 66.1 bis(b) that written opinions of this International Searching Authority will not be so considered.								
	If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of three months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.								
	For further option	For further options, see Form PCT/ISA/220.							
з.	For further details, see notes to Form PCT/ISA/220.								

Name and mailing address of the ISA:



European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465

Authorized Officer

Borowski, A

Telephone No. +49 89 2399-2758



## WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/EP2004/052265

_					
_	Box	No. I Basis of the opinion			
1.	With regard to the <b>language</b> , this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.				
		This opinion has been established on the basis of a translation from the original language into the following language , which is the language of a translation furnished for the purposes of international search (under Rules 12.3 and 23.1(b)).			
2.	With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:				
	a. type of material:				
		a sequence listing			
		table(s) related to the sequence listing			
	b. format of material:				
	Ε	in written format			
		in computer readable form			
	c. time of filing/furnishing:				
	Ĺ	contained in the international application as filed.			
	[	filed together with the international application in computer readable form.			
		furnished subsequently to this Authority for the purposes of search.			
3.		In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.			
4.	Additional comments:				

Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability					
The	e questions whether the claimed vious), or to be industrially applications.	inve able	ntion appears to be novel, to involve an inventive step (to be non have not been examined in respect of:		
	the entire international application,				
×	claims Nos. 19-24				
bed	cause:				
	the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (specify):				
×	the description, claims or drawings (indicate particular elements below) or said claims Nos. 23,24 are so unclear that no meaningful opinion could be formed (specify):				
	see separate sheet				
	the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.				
$\boxtimes$	no international search report has been established for the whole application or for said claims Nos. 19-24				
	the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:				
	the written form		has not been furnished		
			does not comply with the standard		
	the computer readable form		has not been furnished		
			does not comply with the standard		
	the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with the technical requirements provided for in Annex C-bis of the Administrative Instructions.				
	See separate sheet for further of	letail	is		

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

5,10-12

No: Claims

1-4,6-9,13-18

Inventive step (IS)

Yes: Claims

No:

Claims 1-18

Industrial applicability (IA)

Yes: Claims

1-18

No: Claims

2. Citations and explanations

see separate sheet

Box No. VII Certain defects in the international application

The following defects in the form or contents of the international application have been noted:

see separate sheet